S, A., B, A., L, A., Á, C., P, S., T, G., . . . L, C. (2018). Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: Efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Dove Medical Press.
Cita Chicago Style (17a ed.)S, Antolín, et al. Primary Systemic Therapy in HER2-positive Operable Breast Cancer Using Trastuzumab and Chemotherapy: Efficacy Data, Cardiotoxicity and Long-term Follow-up in 142 Patients Diagnosed from 2005 to 2016 at a Single Institution. Dove Medical Press, 2018.
Cita MLA (8a ed.)S, Antolín, et al. Primary Systemic Therapy in HER2-positive Operable Breast Cancer Using Trastuzumab and Chemotherapy: Efficacy Data, Cardiotoxicity and Long-term Follow-up in 142 Patients Diagnosed from 2005 to 2016 at a Single Institution. Dove Medical Press, 2018.